OSE IMMUNOTHERAPEUTICS

OSE Immunotherapeutics' anti-IL-7 Receptor Lusvertikimab results from the CoTikiS Phase 2 trial in Ulcerative Colitis accepted for Oral Presentation at ECCO 2025. Lusvertikimab, a first-in-class IL7 receptor antagonist, demonstrated efficacy and safety in moderate to severe UC, with potential for broader inflammatory and autoimmune diseases.

Plus, news about Disc Medicine, OSE Immunotherapeutics, CrossBridge Bio, Lomond Therapeutics, Relief Therapeutics, and Renexxion: Novo Nordisk, Ascendis Pharma ink deal.

OSE Immunotherapeutics reports H1 2024 results with €82.5 million income, strategic partnerships with AbbVie and Boehringer Ingelheim, and €80.7 million cash position. Clinical highlights include positive Phase 1/2 results for OSE-279 and Lusvertikimab, and the launch of the Artemia Phase 3 study for Tedopi®.

Tulisokibart, an anti-TL1A monoclonal antibody, outperformed placebo in inducing clinical remission at week 12 in moderate to severe ulcerative colitis, according to the ARTEMIS-UC trial. The study incorporated a predictive biomarker for response, showing significant clinical remission, endoscopic improvement, and clinical response in patients on tulisokibart compared to placebo. A phase 3 program is planned to confirm these results.

OSE Immunotherapeutics launches Artemia Phase 3 trial for Tedopi® in second-line NSCLC, targeting HLA-A2+ patients with secondary resistance to ICI, aiming for regulatory registration in Europe and North America.